Reflow Medical

Name: Reflow Medical
Address: 208 Avenida Fabricante, Ste. 100, San Clemente, CA, 92672, US
Telephone: +19494810399

Reflow Medical, Inc. designs and develops technology used to treat cardiovascular disease.

05/29/2026

One year ago, the Spur® Peripheral Retrievable Stent System received FDA De Novo Clearance.
Today, we celebrate more than a regulatory milestone.

Received during NCVH 2025, the clearance marked a defining moment for Reflow Medical.

Over the past year, that milestone has become momentum: growing clinical adoption, expanding scientific evidence, and continued focus on progress in BTK disease treatment.

We are deeply grateful to our clinical partners and to the Reflow Medical team who made this journey possible. Your trust, insight, commitment, and persistence continue to help bring Spur closer to the patients who need it most.

Here’s to one year of FDA De Novo Clearance and to building on this momentum together.

05/28/2026

The stent that leaves nothing behind.
The Breakthrough Device-designated Spur® offers a revolutionary approach to BTK treatment. It provides mechanical support during the procedure and leaves nothing behind.

In CLTI patients with long, calcified infrapopliteal lesions, treatment with the Spur Peripheral Retrievable Stent System following predilatation demonstrated durable safety and efficacy at 12 months.*

The Spur Stent System is intended for the treatment of de novo or restenotic infrapopliteal lesions following predilatation. Through mechanical scaffolding and radially expandable spikes, Spur supports the vessel wall, facilitates blood flow, and enables controlled lesion pe*******on and modification to improve vessel compliance and reduce recoil.

Following treatment, the device is fully retrieved.

Learn more about Spur and its clinical evidence:
https://www.reflowmedical.com/spur/

Full U.S. Indications for Use:
https://www.reflowmedical.com/resources/

*Data on file for DEEPER REVEAL clinical trial (NCT05358353).

05/26/2026

NCVH 2026 starts today.
Stop by Booth 215 from tomorrow at the 2026 NCVH Annual Conference to connect with our team and explore our peripheral endovascular portfolio for complex lesion treatment, including:
• Spur® Peripheral Retrievable Stent System for BTK disease
• Wingman™ CTO Crossing Catheter for the most challenging lesions
• Spex® and Spex® LP Shapeable Support Microcatheters, customizable to a preferred angle

We look forward to welcoming registered fellows today and tomorrow, May 26–27, for didactic education and cadaver-based hands-on training around devices, techniques, and therapy strategies.

Learn more about our products:
https://www.reflowmedical.com/all-products/

05/20/2026

Late-breaking at EuroPCR 2026. And more to come.
Today in Paris, Scott Harding, MD, shared the first 6-month results from the DEEPER CORONARY first-in-human study evaluating the investigational coronary Spur® Elute Sirolimus-Eluting Retrievable Stent System for coronary ISR.

The results demonstrated safety and promising efficacy:
• 100% freedom from MACE
• 100% freedom from all-cause mortality
• Improvement in CCS angina class across all treated patients

For Reflow Medical, these early findings add important clinical momentum to our coronary program and support the continued evaluation of Spur Elute in coronary ISR.

We thank Dr. Harding and all investigators for their excellent work.

Read the full press release: https://www.reflowmedical.com/reflow-medical-reports-six-month-results-from-deeper-coronary-study-of-spur-elute-stent/

05/15/2026

A first look at what may be next in coronary ISR

Join Scott Harding, MD, at EuroPCR 2026 for the first-ever presentation of the 6-month first-in-human clinical results from the DEEPER CORONARY trial, evaluating the coronary Spur® Elute Sirolimus-Eluting Retrievable Stent System for the treatment of in-stent restenosis.

EuroPCR 2026 | Paris, France
May 20, 2026 | 11:15–12:15
Innovation Theatre
Session: Coronary interventions: first-in-man and novel devices

Be among the first to hear the late-breaking clinical data and follow us for more updates on this exciting journey.

05/14/2026

We are looking forward to the 2026 NCVH Annual Conference, May 26–29, in New Orleans.

Visit us at Booth 215 to connect with our team and explore our endovascular portfolio for complex lesion treatment, including the Spur® Peripheral Retrievable Stent System for below-the-knee disease and the Wingman™ Catheter to cross challenging CTOs.

We are also proud to support the NCVH Fellows Course, May 26–27, with didactic education and cadaver-based hands-on training. A great opportunity for fellows to engage with devices, techniques, and therapy strategies.

Learn more about our products:
https://lnkd.in/gtAifsaa

See you in New Orleans.

05/13/2026

How do the latest 12-month DEEPER REVEAL trial data translate into clinical benefit in BTK CLTI?

In patients with long, calcified infrapopliteal lesions, treatment with the Spur® Peripheral Retrievable Stent System following predilatation demonstrated*:

• Meaningful clinical recovery
• Reduced reintervention rates
• Sustained vessel patency

Key safety and efficacy outcomes at 12 months:

• Primary patency: 78.0%
• Freedom from clinically driven TLR: 83.1%
• Complete paired wound healing: 84.3%
• Rutherford class improvement: 80.0%]

These findings highlight the potential of Retrievable Scaffold Therapy (RST) to deliver durable vessel-related and patient-centered outcomes, supporting its role in the treatment of complex BTK disease while leaving nothing behind.

How do you define relevant outcomes for your CLTI patients in daily practice?

🔗 Read the full press release:
https://www.reflowmedical.com/reflow-medical-announces-12-month-results-from-deeper-reveal-trial-sustained-outcomes-with-the-spur-stent-system-in-clti/

🔗 Full U.S. Indications for Use:
https://www.reflowmedical.com/resources/

*At 12 months, vessel-related outcomes in appropriately selected vessels (core lab-measured reference vessel diameter ≥2.5 mm, per study protocol and indication for use) and patient-centered outcomes were assessed.

05/12/2026

RÖKO 2026 is coming up, and our team will be there to connect around complex PAD treatment.

From May 13–15, 2026, Reflow Medical will be onsite at the 107th Deutscher Röntgenkongress in Leipzig.

Visit us at booth CCL7 to meet our team and learn more about our vascular intervention portfolio for CTO crossing, lesion preparation, and temporary scaffolding:
• Wingman™ CTO Crossing Catheter
• Spur® Peripheral Retrievable Scaffold System
• Spex® and Spex® LP Shapeable Support Microcatheters

See you in Leipzig.

05/11/2026

Unmatched Spinning Freedom through a Unique Technology - Now Available in the U.S.

Both Cora Flex® and Cora Force® integrate our proprietary technology Cora Tech™ which sets a new standard for torqueable coronary microcatheters.

Cora Tech™ enables highest bi-directional spinning freedom and best torque transmission compared to market leaders during navigation and crossing of complex coronary lesions.*

Key technology elements:
• No-liner construction for unrestricted torque rotations without liner–guidewire lock-up
• PTFE-coated coils for smooth guidewire advancement
• Stainless steel braid for more predictable torque transmission and precise catheter control

Learn more about our next-generation torqueable microcatheters:
Cora Flex – For everyday complex cases:
https://www.reflowmedical.com/coracatheters/
Cora Force – For the tough cases:
https://www.reflowmedical.com/coracatheters/

* Data on file. Bench testing assessed rotations until loss of guidewire maneuverability as well as peak torque transmission.

Refer to the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, complications, and directions for use:
https://www.reflowmedical.com/resources/

05/06/2026

Everybody needs a Wingman.

When cases get tough, you want a backup you can trust.
The Wingman™ CTO Crossing Catheter is designed to step in when standard tools fall short.

With its unique extendable and rotating beveled needle tip, it is designed to help you cross complex CTOs, right from the occlusion cap through the true lumen.
Its “push and twist” handle gives you intuitive control to anchor, pe*****te, and advance the catheter through the tightest lesions. With a braid-reinforced shaft for strength and a hydrophilic coating for smooth tracking, Wingman is a partner that has been clinically proven to deliver high crossing success and shorter crossing times.
Bring your Wingman when things get tough.

US: https://www.reflowmedical.com/wingman/
CE: https://www.reflowmedical.com/wingman-eu/

Refer to the Instructions for Use for a complete listing of Indications, Contraindications, Warnings, Precautions, Complications, and Directions for Use:
https://www.reflowmedical.com/resources/

Address

208 Avenida Fabricante, Ste. 100
San Clemente, CA
92672

Telephone

+19494810399

Website

http://www.reflowmedical.com/

Alerts

Be the first to know and let us send you an email when Reflow Medical posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Reflow Medical:

Shortcuts

Want your business to be the top-listed Engineering Company in San Clemente?